A1AEA

palazestrant

Created:	2024-02-06
Last modified:	2025-03-19

Find Related PDB Entry
1 entries where A1AEA is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	69
Chiral Atom Count	2
Bond Count	73
Aromatic Bond Count	16

2D diagram of A1AEA

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	palazestrant
Synonyms	(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3-yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
Systematic Name (OpenEye OEToolkits)	(1~{R},3~{R})-2-(2-fluoranyl-2-methyl-propyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole
Formula	C₂₈ H₃₆ F N₃ O
Molecular Weight	449.603
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	CCCN1CC(C1)Oc1ccc(cc1)C1c2[NH]c3ccccc3c2CC(C)N1CC(C)(C)F
SMILES	CACTVS	3.385	CCCN1CC(C1)Oc2ccc(cc2)[CH]3N(CC(C)(C)F)[CH](C)Cc4c3[nH]c5ccccc45
SMILES	OpenEye OEToolkits	2.0.7	CCCN1CC(C1)Oc2ccc(cc2)C3c4c(c5ccccc5[nH]4)CC(N3CC(C)(C)F)C
Canonical SMILES	CACTVS	3.385	CCCN1CC(C1)Oc2ccc(cc2)[C@H]3N(CC(C)(C)F)[C@H](C)Cc4c3[nH]c5ccccc45
Canonical SMILES	OpenEye OEToolkits	2.0.7	CCCN1CC(C1)Oc2ccc(cc2)[C@@H]3c4c(c5ccccc5[nH]4)C[C@H](N3CC(C)(C)F)C
InChI	InChI	1.06	InChI=1S/C28H36FN3O/c1-5-14-31-16-22(17-31)33-21-12-10-20(11-13-21)27-26-24(23-8-6-7-9-25(23)30-26)15-19(2)32(27)18-28(3,4)29/h6-13,19,22,27,30H,5,14-18H2,1-4H3/t19-,27-/m1/s1
InChIKey	InChI	1.06	LBSFUBLFDCAEKV-XHCCPWGMSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB18971
Name	Palazestrant
Groups	investigational
Description	Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Synonyms	1H-Pyrido[3,4-b]indole, 2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1-[4-[(1-propyl-3-azetidinyl)oxy]phenyl]-, (1R,3R)- (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant
CAS number	2092925-89-6

Related Resource References

Resource Name	Reference
PubChem	135351887
ChEMBL	CHEMBL5314475

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.